Condition: Solid Tumor, Adult · Sponsor: CytomX Therapeutics
The purpose of this first-in-human study, CTMX-2051-101, is to characterize the safety, tolerability, and antitumor activity of CX-2051 as a monotherapy and in combination with bevacizumab in adult participants with advanced solid tumors.
This description comes directly from the study's public registry record.
Karen Deane · 650-515-3185 · clinicaltrials@cytomx.com
Always discuss trial participation with your own doctor first.
| Sarah Cannon Research Institute at HealthONE | Denver, Colorado, United States | Recruiting |
| Dana-Farber Cancer Institute | Boston, Massachusetts, United States | Recruiting |
| Montefiore Medical Center | The Bronx, New York, United States | Recruiting |
| Carolina BioOncology Institute, PLLC | Huntersville, North Carolina, United States | Recruiting |
| Sarah Cannon Research Institute, LLC | Nashville, Tennessee, United States | Recruiting |
| START - Dallas/Fort Worth | Fort Worth, Texas, United States | Recruiting |
| START San Antonio LLC | San Antonio, Texas, United States | Recruiting |
| NEXT Virginia | Fairfax, Virginia, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06265688